This cluster groups 2 independently calculated changes: Cash & equivalents increased 8.0%; Operating cash flow increased 33.7%.
2 evidence-backed components· Biological Products, (No Diagnostic Substances)
RESEARCH SNAPSHOTCullinan Therapeutics, Inc.'s latest supported as-filed period reports revenue of $0. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Cash & equivalents increased 8.0%; Operating cash flow increased 33.7%.
2 evidence-backed componentsOperating cash flow changed +33.7% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes. This reverses 4 consecutive comparable moves in the opposite direction.
Each point keeps the date investors could first observe it and its accession.
CGEM · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-387381SEC ↗4Aug 14, 2026Period Aug 13, 20260001193125-26-352523SEC ↗8-KAug 13, 2026Period Aug 12, 20260001193125-26-347400SEC ↗10-QAug 6, 2026Period Jun 30, 20260001193125-26-336717SEC ↗8-KAug 6, 2026Period Aug 6, 20260001193125-26-336700SEC ↗4Jul 7, 2026Period Jul 6, 20260001193125-26-297605SEC ↗4Jul 2, 2026Period Jun 30, 20260001193125-26-294869SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Sep 8, 2026Filed Sep 10, 2026 | Michaelson JenniferChief Scientific Officer | Option ExerciseDirect | 4,000 | $4 | $17,200 | Form 4 ↗ |
| Sep 8, 2026Filed Sep 10, 2026 | Michaelson JenniferChief Scientific Officer | Open Market SaleDirect | 8,000 | $22 | $172,560 | Form 4 ↗ |
| Sep 8, 2026Filed Sep 10, 2026 | Michaelson JenniferChief Scientific Officer | Option ExerciseDirect | 4,000 | $0 | $0 | Form 4 ↗ |
| Aug 13, 2026Filed Aug 14, 2026 | Michaelson JenniferChief Scientific Officer | Option ExerciseDirect | 30,000 | $4 | $129,000 | Form 4 ↗ |
| Aug 13, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Current liabilities changed +44.8% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Working capital / assets changed +3520 basis points from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Current assets changed +23.9% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Working capital changed +21.6% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Operating income changed +24.5% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Total assets changed -30.1% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-294863| Michaelson JenniferChief Scientific Officer |
| Open Market SaleDirect |
| 30,000 |
| $20 |
| $607,800 |
| Form 4 ↗ |
| Aug 13, 2026Filed Aug 14, 2026 | Michaelson JenniferChief Scientific Officer | Option ExerciseDirect | 30,000 | $0 | $0 | Form 4 ↗ |